Free Trial

KALA BIO (KALA) 10K Form and Latest SEC Filings 2026

KALA BIO logo
$0.12 +0.00 (+2.68%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$0.12 0.00 (-0.09%)
As of 06:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest KALA BIO SEC Filings & Recent Activity

KALA BIO (NASDAQ:KALA) has submitted 401+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-K submitted on April 15, 2026.

10-K
KALA BIO Files Annual Report on Apr. 15, 2026

The 10-K contains KALA BIO's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

KALA BIO SEC Filing History

Browse KALA BIO's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/15/2026 3:03 PM
KALA BIO (1479419) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/12/2026 4:40 PM
KALA BIO (1479419) Subject
Rosen Howard B (1307068) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2026 8:16 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 11:15 PM
KALA BIO (1479419) Filer
Form EFFECT
02/09/2026 3:15 PM
Berger Chaim D. (2110273) Reporting
KALA BIO (1479419) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/09/2026 3:15 PM
Colman Yonatan C. (2110255) Reporting
KALA BIO (1479419) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/09/2026 3:15 PM
KALA BIO (1479419) Issuer
Minkowitz Avraham (2110204) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/09/2026 3:16 PM
KALA BIO (1479419) Issuer
Posen Hillel D. (2109561) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/09/2026 3:16 PM
KALA BIO (1479419) Issuer
Purdy Brendan P. (2110412) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/06/2026 3:14 PM
KALA BIO (1479419) Subject
Lazar David E. (1932843) Filed by
Form SCHEDULE 13D
02/02/2026 5:01 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/26/2026 3:05 PM
KALA BIO (1479419) Filer
Form DEFA14A
01/23/2026 3:05 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2026 7:00 AM
KALA BIO (1479419) Subject
LIFESCI CAPITAL, LLC (1580446) Filed by
Form SCHEDULE 13G
01/08/2026 3:05 PM
KALA BIO (1479419) Filer
Form 424B5
01/08/2026 3:07 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 3:05 PM
KALA BIO (1479419) Filer
Form DEFA14A
01/06/2026 6:30 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 3:15 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 3:12 PM
KALA BIO (1479419) Filer
Form DEF 14A
12/29/2025 3:52 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/22/2025 4:18 PM
KALA BIO (1479419) Issuer
Lazar David E. (1932843) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 4:18 PM
KALA BIO (1479419) Filer
Form PRER14A
12/16/2025 12:28 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 8:32 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2025 3:05 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2025 5:00 AM
KALA BIO (1479419) Filer
Form 424B5
12/03/2025 3:51 PM
KALA BIO (1479419) Subject
OXFORD FINANCE LLC (1556257) Filed by
Form SCHEDULE 13G
12/03/2025 4:00 PM
KALA BIO (1479419) Issuer
OXFORD FINANCE LLC (1556257) Reporting
Form 3
Initial statement of beneficial ownership of securities  
12/02/2025 5:30 AM
KALA BIO (1479419) Issuer
Lazar David E. (1932843) Reporting
Form 3/A
11/26/2025 1:50 PM
KALA BIO (1479419) Issuer
Lazar David E. (1932843) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/26/2025 2:03 PM
KALA BIO (1479419) Issuer
Lazar David E. (1932843) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 3:15 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/19/2025 6:26 AM
KALA BIO (1479419) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2025 12:07 PM
Cormorant Asset Management, LP (1583977) Filed by
KALA BIO (1479419) Subject
Form SCHEDULE 13G/A
11/10/2025 7:00 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 7:00 PM
KALA BIO (1479419) Issuer
Kharabi Darius (1893729) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 7:00 PM
Brazzell Romulus K (1298079) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 7:00 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 7:00 PM
KALA BIO (1479419) Issuer
Reumuth Mary (1710969) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 7:00 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2025 6:03 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2025 3:02 PM
KALA BIO (1479419) Subject
Reumuth Mary (1710969) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2025 6:07 PM
KALA BIO (1479419) Subject
Reumuth Mary (1710969) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2025 5:21 PM
Brazzell Romulus K (1298079) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2025 5:08 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2025 4:10 PM
KALA BIO (1479419) Subject
Kharabi Darius (1893729) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/20/2025 7:00 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2025 5:24 PM
KALA BIO (1479419) Subject
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Filed by
Form SCHEDULE 13D/A
10/03/2025 8:06 AM
BAKER BROS. ADVISORS LP (1263508) Filed by
KALA BIO (1479419) Subject
Form SCHEDULE 13G
10/02/2025 7:37 PM
BAKER BROS. ADVISORS LP (1263508) Filed by
KALA BIO (1479419) Subject
Form SCHEDULE 13D/A
10/02/2025 3:47 PM
Baker Bros. Advisors (0) GP
BAKER BROS. ADVISORS LP (1263508) Reporting
BAKER FELIX (1087940) Reporting
BAKER JULIAN (1087939) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 6:31 PM
KALA BIO (1479419) Subject
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Filed by
Form SCHEDULE 13D/A
10/01/2025 7:00 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 7:08 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2025 3:24 PM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 4:28 PM
KALA BIO (1479419) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
09/11/2025 3:02 PM
KALA BIO (1479419) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13G
09/02/2025 3:08 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2025 7:08 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2025 7:01 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2025 7:06 AM
KALA BIO (1479419) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/09/2025 7:08 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/26/2025 7:00 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 7:00 PM
Brazzell Romulus K (1298079) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 7:00 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 7:00 PM
KALA BIO (1479419) Issuer
Reumuth Mary (1710969) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 7:00 PM
KALA BIO (1479419) Issuer
Kharabi Darius (1893729) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 7:00 PM
KALA BIO (1479419) Subject
Kharabi Darius (1893729) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025 7:00 PM
KALA BIO (1479419) Subject
Reumuth Mary (1710969) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025 7:01 PM
Brazzell Romulus K (1298079) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025 7:01 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025 7:02 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2025 7:00 PM
KALA BIO (1479419) Issuer
KOVEN ANDREW I (1258673) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:00 PM
KALA BIO (1479419) Issuer
Myers C. Daniel (1489533) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:00 PM
KALA BIO (1479419) Issuer
PERRY GREGORY D (1236371) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:00 PM
Farid Marjan (1952098) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:00 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 7:00 PM
KALA BIO (1479419) Issuer
Rosen Howard B (1307068) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 8:44 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Issuer
Form 4/A
06/04/2025 7:00 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 7:00 PM
Brazzell Romulus K (1298079) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 7:00 PM
Bazemore Todd (1605767) Reporting
KALA BIO (1479419) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 7:00 PM
KALA BIO (1479419) Issuer
Reumuth Mary (1710969) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 7:00 PM
KALA BIO (1479419) Issuer
Kharabi Darius (1893729) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 7:10 PM
Iwicki Mark T (1415537) Reporting
KALA BIO (1479419) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2025 7:01 AM
KALA BIO (1479419) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

KALA BIO SEC Filings - Frequently Asked Questions

KALA BIO (KALA) has submitted 401+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

KALA BIO's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 10-K submitted on April 15, 2026. This was the company's annual report for fiscal year 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KALA) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners